The hypothesis is that from a cluster defined by a confirmed positive case of COVID-19 and its contact cases, it is possible to study the different expressions and clinical evolutions of COVID-19 infection and to explore the biological profiles related to the observed clinical history. Certain biological determinants (virological, immunological, microbological or gentic) could indeed be correlated with the clinical presentation and/or be useful for personalized care. The main objective is to study the relationship between the biological profiles observed and the clinical evolutions within the same cluster of transmission of the coronavirus SARS-CoV-2 (positive COVID-19 cases and contact subjects).
Subjects with a COVID-19 infection and thei contact cases (identification according to health
insurance criteria, see "Améli.fr") will be offered a clinical evaluation and the takin of
biological samples, whether they are hospitalized or via the outpatient screening channel.
For the main objective: during the D0 visit, the subjects who agreed to participate in the
study will have a clinical evaluation according to a standardized questionnaire and a
nasopharyngeal swab, saliva, blood, stool and urine.
For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index
cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final
consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and
urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19
serology.
Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see "Améli.fr") will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.
For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.
For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.
Inclusion Criteria:
- Child or adult, no age limit
- Able to give informed consent to participate in research
- If a minor participant: consent of the legal representatives
- If confirmed case COVID-19 (symptomatic or asymptomatic): laboratory result confirming
infection with SARS-CoV-2 by RT-PCR or by serology
- If contact case: people identified as a risk contact according to the criteria of the
"Amélie.fr" health insurance
Exclusion Criteria:
- Subjects under tutorship, curatorship, deprived of liberty, safeguard of justice
- Refusal of the child
- Refusal of participation
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Investigator: Lise Laclautre
Contact: +33473754963
promo_interne_drci@chu-clermontferrand.fr
Investigator:
Lise LACLAUTRE
+33473754963
promo_interne_drci@chu-clermontferrand.fr
Céclie Henquell, Principal Investigator
University Hospital, Clermont-Ferrand